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1. BACKGROUND {#cam41925-sec-0005}
=============

Research on the overuse of medical tests in inpatient and outpatient medical practice[1](#cam41925-bib-0001){ref-type="ref"}, [2](#cam41925-bib-0002){ref-type="ref"}, [3](#cam41925-bib-0003){ref-type="ref"}, [4](#cam41925-bib-0004){ref-type="ref"} has lead to organizations such as Choosing Wisely[5](#cam41925-bib-0005){ref-type="ref"}, [6](#cam41925-bib-0006){ref-type="ref"} and Right Care[7](#cam41925-bib-0007){ref-type="ref"}, [8](#cam41925-bib-0008){ref-type="ref"} as well as the concepts around "Do not Do"[9](#cam41925-bib-0009){ref-type="ref"} and OverDiagnosis.[10](#cam41925-bib-0010){ref-type="ref"} The overuse of medical tests is simply the ordering of tests that are unnecessary and represents poor resource utilization. Due to many factors including the media, the public, and many physicians believe that more tests are better as they might uncover treatable disease[11](#cam41925-bib-0011){ref-type="ref"}, [12](#cam41925-bib-0012){ref-type="ref"}; in clinical practice, physicians order routine tests or panels of routine tests for many reasons including defensive medicine.[13](#cam41925-bib-0013){ref-type="ref"}

The indiscriminant or inappropriate use of routine tests will uncover subclinical malignant and nonmalignant disease in the general population but the term OverDiagnosis specifically refers to "disease that ultimately will not cause symptoms or early death."[12](#cam41925-bib-0012){ref-type="ref"} In oncology, this refers to the identification of small, asymptomatic, or undetectable cancers that may never become symptomatic or life‐threatening.[14](#cam41925-bib-0014){ref-type="ref"}, [15](#cam41925-bib-0015){ref-type="ref"} Routine screening with tests such as prostate‐specific antigen, mammography, neck ultrasound, and computed tomography chest are all known to be associated with the OverDiagnosis of prostate,[16](#cam41925-bib-0016){ref-type="ref"} breast,[17](#cam41925-bib-0017){ref-type="ref"} thyroid,[18](#cam41925-bib-0018){ref-type="ref"}, [19](#cam41925-bib-0019){ref-type="ref"} and lung[20](#cam41925-bib-0020){ref-type="ref"} cancers, respectively. Other cancers that have been implicated in the OverDiagnosis story include uterus,[21](#cam41925-bib-0021){ref-type="ref"} kidney,[15](#cam41925-bib-0015){ref-type="ref"} melanoma,[22](#cam41925-bib-0022){ref-type="ref"} and esophagus[23](#cam41925-bib-0023){ref-type="ref"} all of which can be uncovered by specific tests that can be ordered or performed with minimal indications.

The objective of the study was to determine whether variations in the use of routine laboratory and imaging testing by physicians were associated with variations in the rates of cancer detection in their patients. The universal health insurance program and the availability of linked health care data on all patients at the Institute of Clinical Evaluative Sciences in the province of Ontario, Canada provides the opportunity to answer this question.

2. MATERIALS AND METHODS {#cam41925-sec-0006}
========================

2.1. Study design {#cam41925-sec-0007}
-----------------

This is a retrospective population‐based cohort study using electronic health care data from all 13 million residents in the Province of Ontario, Canada. Ontario has 14 health care regions (Local Health Integration Networks (LHIN)) subdivided into 97 subLHINs (3‐15 per LHIN). We utilized the data holdings of the Institute of Clinical Evaluative Sciences (ICES) including all health care‐related events for the patient population linked using an anonymous unique identifier for each person from 1/1/2008 to 12/31/2012.

2.2. Data sources {#cam41925-sec-0008}
-----------------

The Ontario Health Insurance Plan (OHIP) contains physician billing data including diagnostic tests (test type, date, referring doctor).The Ontario Cancer Registry (OCR) is a passive cancer registry based on all pathology reports with a diagnosis of cancer in Ontario.The Ontario Registered Person\'s Database provides demographic information on all residents of Ontario who are eligible for OHIP.The ICES Physician Database (IPDB) provides demographic and specialization data on all active physicians in Ontario.The Canadian Institute for Health Information data includes inpatient and outpatient hospitalization data on all patients in Canada.The Office of the Ontario Registrar General provides information on vital status (date and cause of death) on residents of Ontario.The Client Agency Program Enrolment (CAPE) is a registry created at ICES of patients enrolled (rostered) in primary care group practices and the physician to whom they are rostered. CAPE dataset identified the Usual Providers of Care (UPCs).

2.3. Study population {#cam41925-sec-0009}
---------------------

The patient population included all adults age 40‐75 as of 1/1/2008 excluding 7773 women who gave birth during study period (as they would have had more tests) and patients without health care coverage (Figure [1](#cam41925-fig-0001){ref-type="fig"}). Patients who became ineligible for health care coverage after 2008 (109 271) were included until ineligibility. Approximately 3% of the population is not covered by the provincially funded universal health care (OHIP) and we have no access to information on them. These include transients, tourists, and those covered by Federal health insurance including active members of armed forces, indigenous persons living on reserves, inmates of federal prisons and some refugees.

![Flowchart of study population](CAM4-8-850-g001){#cam41925-fig-0001}

In Ontario, Canada, most patients register or "sign on" to a single family physician in a group of family physicians who are then paid by the government by a mix of capitation payment, fee‐for‐service, and incentive fees. Although rostered patients can and do go to the ER and to "walk‐in" clinics, they usually are seen by their registering family doctor or another provider in the same group. They do not attend other family doctors groups. We identified the Usual Providers of Care (UPCs) caring for the study population 2008‐2012. Physicians without complete information in the ICES Physician Database (age, sex, practice type), those with small practices (\<200 rostered patients) (3996), and those who were not primarily involved with primary care (9607) were excluded. Also, excluded were 263 478 patients who were not rostered to a study UPC or rostered at all as we wanted to look at the tests and cancers of patients who were going to their regular doctor if they had one.

2.4. Patient characteristics {#cam41925-sec-0010}
----------------------------

Area‐level socioeconomic status (SES) of location‐specific income quintiles was based on Statistics Canada 2006 census data matched to postal codes providing data at level of enumeration units (neighborhoods)Comorbidity was estimated using the Elixhauser Index[24](#cam41925-bib-0024){ref-type="ref"}, [25](#cam41925-bib-0025){ref-type="ref"}, [26](#cam41925-bib-0026){ref-type="ref"} based on hospital discharge data with look back of 2 years (1/1/2006 to 12/31/2007). Elixhauser created a summative scale over 31 domains for administrative data and we used the cut‐points of 0, 1, 2, \>2 with greater comorbidity creating higher scores.[27](#cam41925-bib-0027){ref-type="ref"}, [28](#cam41925-bib-0028){ref-type="ref"}, [29](#cam41925-bib-0029){ref-type="ref"}Time on study was the number of consecutive patient days from 1/1/2008 to the earliest date of death, loss OHIP eligibility or end of study period (12/31/2012).Rurality was based on the Statistics Canada Postal Code Conversion File from the 2006 census and reported by Metropolitan Influence Zones (MIZ).

2.5. UPC characteristics {#cam41925-sec-0011}
------------------------

Age, sex, years in practice and practice type (in 2008).

2.6. Study cancers and patient cancer rates {#cam41925-sec-0012}
-------------------------------------------

The outcome of interest was a new diagnosis of cancer. Based on the potential for OverDiagnosis, 11 cancers were selected including thyroid and prostate (definite) and breast, Non‐Hodgkin\'s Lymphoma, kidney, melanoma, uterus (possible). Cancers of ovary, lung, esophagus, and pancreas were included as controls. We assumed that almost all the aggressive cancers would progress within our time frame, would become clinically apparent and therefore be diagnosed at the same rates regardless of rates of medical tests. We calculated age‐sex standardized cancer incidence rates for each cancer (cases/10 000 patient years).

2.7. Test selection and utilization {#cam41925-sec-0013}
-----------------------------------

A panel of common laboratory and imaging tests was developed based on meetings with 5 local family physicians (academic and community‐based) and a general internist. Tests had to be common, routinely ordered, potentially overused as screening tests and span a wide variety of clinical indications. Cancer‐specific tests with either formal cancer screening programs (fecal occult blood, mammography) or informal cancer screening (prostate‐specific antigen, Papanicolaou test) were excluded. A total of 27 tests were selected (see Table 3).

This study was about the impact of the variation in the rates of use of tests and therefore to establish a relationship between the rates of test use and rates of cancer diagnoses, tests had to demonstrate variation in use. To compare test rates, we first calculated the total \# of each test performed on the population of each subLHIN and then age and sex standardized each subLHIN\'s test rates (\# of tests/10 000 person‐years) to the entire study population. We assessed test rate variation by comparing test rates across the small geographic subLHINs using the Systematic Component of Variation (SCV)[30](#cam41925-bib-0030){ref-type="ref"}, [31](#cam41925-bib-0031){ref-type="ref"} for each test for each subLHIN. According to Appleby et al,[30](#cam41925-bib-0030){ref-type="ref"} the SCV is the appropriate measurement of variation for research in this setting, SCVs greater than 3 are likely to be due largely to differences in practice style or medical discretion, SCVs up to 10 are considered high variation and SCVs \>10 very high variation.

2.8. Physician test utilization {#cam41925-sec-0014}
-------------------------------

We calculated observed‐to‐expected (O/E) ratios for each UPC for each test using indirect standardization, using the entire study population as the standard population. Indirect standardization was used as we were investigating variations in test utilization across physicians relative to the whole study population; indirect standardization allowed us to explore these variations while removing the confounding effect of patient age and sex. Observed (actual) counts were the \# of tests in study period of those patients in the practice of each UPC for their patient years. The expected count was the \# tests a UPC might order based on his/hers case mix if his/her test utilization was identical to that observed in the entire study population. This count was done by initially calculating a rate for each of 14 age/sex strata (ie, male 40‐44, female 70‐75 etc) across Ontario for each test for the total patient years in each strata. An expected count was estimated for each strata, with the total sum being the expected count for each UPC for each test. To create composite O/E ratios for all the laboratory tests and all the imaging tests for each UPC, all of their patients observed 13 laboratory test and 10 imaging test counts were summed. Then, the expected counts for the total laboratory and imaging tests for all those patients were generated using indirect patient age‐sex standardization for each UPC. The combined test O/E ratios are based on the ratio of the combined total observed and total expected test counts (13 laboratory tests or 10 imaging test).

2.9. Physician testers {#cam41925-sec-0015}
----------------------

To assess over and underuse of tests by UPCs, we created 6 levels of physician testers based on the O/E ratios of all the UPCs for the combined laboratory and for the combined imaging tests. Six levels were the smallest number of groups that could provide estimates for lower and typical testers as well as the opportunity to assess dose‐response.. Typical testers were defined as an O/E ratio of 0.75‐1.25. We selected \<0.5 for strong lower testers, 0.5‐0.75 for mild lower testers, 1.25‐1.5 for mild higher testers, 1.5‐2.0 for moderate higher testers and \>2.0 for strong higher testers. The thresholds for all tester groups were defined a priori and were based on our assumption that a 25% and especially a 50% increase or decrease in the ordering of routine tests would be of clinical significance.

2.10. UPC testers vs cancer incidence {#cam41925-sec-0016}
-------------------------------------

The relationship between tester groups and cancer incidence rates was evaluated by examining age‐sex standardized incidence rates and risk ratios.

2.11. Statistical analysis {#cam41925-sec-0017}
--------------------------

All statistical tests were two‐sided with significance of 0.05. Poisson regression models were used to control for effects of patient and UPC variables on the risk of cancer diagnoses. Patients with missing or incomplete variable data were not included in the modelling.

3. RESULTS {#cam41925-sec-0018}
==========

3.1. Study population and cancers {#cam41925-sec-0019}
---------------------------------

The study populations included 4 923 765 residents of Ontario and 6849 UPCs (Table [1](#cam41925-tbl-0001){ref-type="table"}). There was no difference in patient age or comorbidity across the tester groups. Males, rural patients, and lower SES tended toward few tests. At least one of the 11 study cancers was diagnosed in 139 248 patients during 2008‐2012 (Table [2](#cam41925-tbl-0002){ref-type="table"}). Prostate, breast, and lung had the greatest number of new cases and the highest rates of new cases. Ovary, pancreas, and esophagus were the least common new diagnoses.

###### 

Patient Characteristics (n = 4,923,765) (\*\* due to missing or incorrect address/postal code or classifications, there are missing data in some cells)

  Variable                               Total    Laboratory tests   Imaging tests                              
  -------------------------------------- -------- ------------------ --------------- -------- -------- -------- --------
  Age (mean)                             54.4 y   54.5 y             54.3 y          54.4 y   54.3 y   54.5 y   54.3 y
  Sex                                                                                                           
  Male, %                                48.28    50.91              47.67           46.41    51.55    47.04    45.47
  Elixhauser comorbidity index, %                                                                               
  0                                      93.40    93.1               93.56           93.48    93.56    93.32    93.30
  1                                      3.81     3.95               3.73            3.78     3.64     3.89     3.94
  2                                      1.51     1.57               1.47            1.49     1.50     1.51     1.52
  \>2                                    1.28     1.37               1.24            1.24     1.30     1.28     1.24
  Neighborhood income quintiles\*\*, %                                                                          
  1 (Lowest)                             17.57    18.76              17.10           17.02    18.73    16.75    17.16
  2                                      19.42    19.27              19.26           19.82    19.85    19.18    19.17
  3                                      19.88    19.48              19.77           20.47    19.63    19.79    20.38
  4                                      21.07    20.32              21.33           21.45    20.35    21.28    21.77
  5 (Highest)                            21.77    21.75              22.27           21.01    21.12    22.71    21.27
  NA/Unknown                             0.30     0.42               0.26            0.23     0.33     0.30     0.26
  Rurality\*\*, %                                                                                               
  Urban                                  87.20    80.42              88.64           92.24    85.90    86.45    90.25
  Strong MIZ                             5.53     6.40               5.76            4.25     5.77     5.46     5.31
  Moderate MIZ                           4.84     7.49               4.31            2.81     5.27     5.60     3.03
  Weak/No MIZ                            2.42     5.67               1.28            0.70     3.04     2.48     1.41
  NA/Unknown                             0.01     0.02               0.01            0.01     0.02     0.01     0.01

John Wiley & Sons, Ltd

###### 

The 139,248 new cancers diagnosed in the study population between Jan 1, 2008 and Dec 31, 2012

  Cancer                    Total no. of diagnoses   Total no. of person‐years (PY)   Rate (no. of diagnoses per 10 000 PY)
  ------------------------- ------------------------ -------------------------------- ---------------------------------------
  Thyroid                   7823                     24 085 903.58                    3.25
  Breast                    30 240                   12 439 627.67                    24.31
  Ovarian                   3629                     12 502 365.33                    2.90
  Uterus                    7928                     12 492 233.33                    6.35
  Prostate                  34 072                   11 512 565.67                    29.60
  Esophagus                 2390                     24 101 589.25                    0.99
  Kidney                    7157                     24 089 698.25                    2.97
  Lung                      26 813                   24 076 212.58                    11.14
  Melanoma                  7671                     24 086 996.50                    3.19
  Pancreas                  4577                     24 100 576.75                    1.90
  Non‐Hodgkin\'s Lymphoma   8934                     24 086 875.33                    3.71
  ≥1 Above Cancers          139 248                                                   

John Wiley & Sons, Ltd

3.2. Test utilization {#cam41925-sec-0020}
---------------------

There were large differences in overall rates (tests/100 patient years) and in the variations in the rates for the selected tests across the 97 subLHINs (data not included). Chest X‐ray and Abdominal Ultrasound had the highest median rates and Limb CT, Neck Ultrasound and Spine CT had the highest variations in rates for imaging tests. Serum cholesterol/triglycerides, electrolytes, and Glutamate Pyruvate Transaminase had the highest median rates, and Ferritin, Vitamin B12, and Alkaline Phosphatase the highest variation in rates for the laboratory group.

We rejected 4 tests with SVC less than 3 (X‐ray of chest, foot and knee, and pelvic CT scans). A total of 22 tests with SCV range between 5.9 and 38.9 were selected for evaluation. Abdominal Ultrasound (SCV = 2.4) was retained as it was included in previous work.[18](#cam41925-bib-0018){ref-type="ref"}

3.3. O/E ratios for UPCs {#cam41925-sec-0021}
------------------------

Table [3](#cam41925-tbl-0003){ref-type="table"} lists the mean, maximum, and Inter‐quartile range (IQR) values of the O/E ratios for all UPCs for the selected tests. The laboratory tests with the highest O/E ratios were Anti‐Nuclear Antibody, Erythrocyte Sedimentation Rate and Creatinine. Similarly, the imaging tests with the highest ratios were abdominal X‐ray, neck ultrasound and limb ultrasound.

###### 

The Observed/Expected Ratios for the laboratory and imaging tests

  Test group                              Test                   Mean     Max           Inter quartile range (IQR)
  --------------------------------------- ---------------------- -------- ------------- ----------------------------
  Lab                                     Alkaline phosphatase   0.947    8.500         0.241‐1.465
  Antinuclear antibody test               0.979                  45.566   0.243‐1.209   
  Complete blood count                    0.966                  5.742    0.662‐1.264   
  Cholesterol/Triglycerides               0.960                  4.538    0.668‐1.251   
  Creatinine                              0.964                  11.565   0.647‐1.262   
  Electrolytes                            0.977                  5.833    0.417‐1.399   
  Erythrocyte sedimentation rate          0.963                  25.196   0.243‐1.113   
  Ferritin                                0.971                  9.304    0.259‐1.517   
  Glycosylated hemoglobin                 0.945                  6.917    0.471‐1.282   
  High‐density lipoprotein                0.960                  4.555    0.666‐1.252   
  Serum glutamate pyruvate transaminase   0.973                  6.150    0.504‐1.296   
  Thyroid‐stimulating hormone             0.963                  5.806    0.572‐1.323   
  Vitamin B12                             0.971                  9.936    0.262‐1.527   
  Imaging                                 Abdominal CT           0.962    8.589         0.382‐1.305
  Abdominal ultrasound                    0.955                  16.380   0.441‐1.214   
  Abdominal X‐ray                         0.992                  46.193   0.193‐1.230   
  Bone mineral density                    0.957                  5.980    0.504‐1.312   
  Bone Scan                               0.920                  17.078   0.233‐1.199   
  Carotid and/or artery ultrasound        0.965                  15.804   0.352‐1.272   
  Head CT                                 0.969                  7.181    0.257‐1.403   
  Limb ultrasound                         0.958                  20.094   0.342‐1.272   
  Neck ultrasound                         0.944                  39.435   0.331‐1.072   
  Spine CT                                0.934                  14.653   0.137‐1.238   

John Wiley & Sons, Ltd

3.4. UPC tester groups {#cam41925-sec-0022}
----------------------

The distribution of the UPC tester groups (Strong Lower Testers, Mild Lower Testers, Typical Testers, Mild Higher Testers, Moderate Higher Testers, Strong Higher Testers) based on the O/E ratios for both the laboratory and imaging test groups are presented on Figure [2](#cam41925-fig-0002){ref-type="fig"}. 26% and 24% of the UPCs were higher testers for laboratory and imaging, respectively. 33% and 38% of the UPCs were lower testers for laboratory and imaging tests. Overall, UPCs in the Typical Tester group ordered an average of 18,688 laboratory and 669 imaging tests in 2008‐2012. The Higher Testers ordered on average 59% (29,800) more laboratory and 80% (1,207) more imaging tests than the Typical Testers. The Lower Testers ordered on average 61% (7,259) fewer laboratory and 57% fewer imaging tests. The distributions for 3 Higher Tester groups for both laboratory and imaging tests were stable over time comparing the cohorts of 1/1/08‐31/5/10 to 1/6/10 to 31/12/12 (data not included).

![The distributions of the UPC test users based on O/E ratios for both imaging and laboratory tests](CAM4-8-850-g002){#cam41925-fig-0002}

3.5. Cancer rates by UPC tester groups {#cam41925-sec-0023}
--------------------------------------

The age‐sex standardized rates (cases/10 000 patient years) for our study population of select cancers by the UPC tester groups are presented on Figure [3](#cam41925-fig-0003){ref-type="fig"}. Only thyroid cancer had significantly higher cancer incidence rates in all higher testers (average rates of 4.2/10 000 patient years and 4.4/10 000 patient years among all higher testers of laboratory and imaging tests vs. overall rate of 3.2/10 000 patient years) and lower cancer incidence rates in all lower testers (average rates of 2.7/10 000 patient years and 2.7/10 000 patient years among all lower testers of laboratory and imaging tests vs. overall rate of 3.2/10 000 patient years) for both the laboratory and imaging groups of tests (Figure [3](#cam41925-fig-0003){ref-type="fig"}A,B). Prostate cancer demonstrated increased incidence rates with some of higher tester groups for both laboratory and imaging (rates of 32.7/10 000 patient years among strong higher tester of laboratory tests and 31.3/10 000 patient years among moderate higher tester of imaging tests vs. overall rate of 29.6/10 000 patient years) and decreased incidence rates with some of the lower tester laboratory and imaging groups (rates of 28.5/10 000 patient years among moderate lower tester of laboratory tests and 28.6/10 000 patient years among strong lower tester of imaging tests vs. overall rate of 29.6/10 000 patient years) (Figure [3](#cam41925-fig-0003){ref-type="fig"}C,D). Pancreas cancer had higher incidence in the moderate higher imaging testers group of UPCs (Figure [3](#cam41925-fig-0003){ref-type="fig"}F). Of the remaining 8 study cancers (breast, ovary, lung, esophagus, uterus, kidney, melanoma, and NHL), none had statistically significant increases in rates with increasing testing noting that breast, uterus, kidney (Figure [3](#cam41925-fig-0003){ref-type="fig"}E) and Non‐Hodgkins Lymphoma demonstrated nonstatistically significant increases in rates with some higher imaging user groups.

![The age/sex standardized rates (cases/10 000 patient years) for the UPC laboratory and imaging tester groups. The horizontal line is the overall cancer rate for the study population](CAM4-8-850-g003){#cam41925-fig-0003}

3.6. Rate Ratios (RRs) of a cancer diagnosis by UPC tester groups {#cam41925-sec-0024}
-----------------------------------------------------------------

The cancer incidence RRs for UPC test groups when controlling for patient factors (age, sex, and comorbidity) and physician factors (age and sex) are presented for select cancers on Figure [4](#cam41925-fig-0004){ref-type="fig"}. The overall results are reported in Table [S1](#cam41925-sup-0001){ref-type="supplementary-material"}. The reference group is the Typical Testers. Similar to the results of rates on Figure [3](#cam41925-fig-0003){ref-type="fig"}, thyroid (Figure [4](#cam41925-fig-0004){ref-type="fig"}A,B) was the only cancer to be diagnosed more by all higher testers and less by all lower testers for both laboratory and imaging tests. The only other cancers to have significant increases with increasing use of tests were prostate (Figure [4](#cam41925-fig-0004){ref-type="fig"}C) and pancreas cancers (Figure [4](#cam41925-fig-0004){ref-type="fig"}E). Of the remaining 8 study cancers (breast, ovary, lung, esophagus, uterus, kidney, melanoma, and NHL), none had statistically significant risk (ie, OR = 1.0) with increasing testing noting that breast, uterus and Non‐Hodgkins Lymphoma (Figure [4](#cam41925-fig-0004){ref-type="fig"}D), demonstrated nonsignificant increases with more tests. Adjustment for additional physician factors (years in practice) or patient factors (income, rurality, and deprivation) or using sex‐stratified analyses changed the levels of significance but not the significant results.

![The Rate Ratios (RRs) for cancer risk (adjusted for patient age, patient sex, patient comorbidity, UPC age, UPC sex). Typical testers are the control group in the regression model](CAM4-8-850-g004){#cam41925-fig-0004}

4. DISCUSSION {#cam41925-sec-0025}
=============

The objective of this study was to determine whether variations in the overall rates of ordering routine laboratory and imaging testing by physicians were associated with variations in the rates of cancer detection in their patients. Our method included a variety of selected tests noting that patients will have had these tests performed for legitimate reasons, for unrelated but important reasons, and for no reason aside from screening. There is no information on what the correct, ideal, or appropriate rates of our selected tests might be across a population and we based our classification of testers on the test rates of the average or Typical Testers. Our results are not meant to reflect ideal testing physicians or ideal treating physicians. We found that 24% and 26% of physicians were higher laboratory and imaging testers, respectively, compared to their peers and as expected that thyroid cancer and prostate cancers were diagnosed more by higher laboratory testers and higher imaging testers. These findings are consistent with the literature on screening, OverDiagnosis and subsequent overtreatment for both thyroid and prostate cancer. We also found that the patients of doctors who were lower testers were diagnosed with fewer thyroid cancers. We did not expect to and did not find a relationship between higher testing and cancers of lung, esophagus and ovary. Nonstatistically significant trends were seen in other cancers implicated in the OverDiagnosis literature (breast, uterus, kidney) suggesting that the overuse of tests, subclinical disease, and a proportion of indolent cases along with the potential for overtreatment might be part of the stories in those cancers. Unexpectedly, we found that the patients of doctors who were lower testers were diagnosed with more ovary, lung, esophagus and kidney cancers; reasons for this (perhaps social reasons by patients) would be speculative and are outside the scope of this study.

Our finding that rates of pancreas cancer are related to rates of routine testing (Figures [3](#cam41925-fig-0003){ref-type="fig"}F and [4](#cam41925-fig-0004){ref-type="fig"}D) was unexpected. Pancreas cancer was diagnosed more often by the Moderate higher imaging tester group and had consistent marginal results throughout all the analyses of imaging tests. The incidence of pancreas cancer is not changing in Canada[32](#cam41925-bib-0032){ref-type="ref"} and mortality is slowly declining.[33](#cam41925-bib-0033){ref-type="ref"} In the United States, however, the incidence is slowly rising and mortality is flat[34](#cam41925-bib-0034){ref-type="ref"} which is the typical pattern of an overdiagnosed cancer.[15](#cam41925-bib-0015){ref-type="ref"} There appears to be a role for screening the \<10% of patients with a family history and there are recognized premalignant lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm) that potentially could be picked up by high testers. The other surprise cancer was Non‐Hodgkins Lymphoma. Although the rates for Non‐Hodgkins Lymphoma never achieved statistical significance, evidence of a marginal increase in rates with higher users was a consistent finding throughout our analysis unlike all the other cancers we tested. The incidence of Non‐Hodgkins Lymphoma is declining and survival is improving in Canada and the United States.

We made a number of assumptions for this study. We, for example, assumed that doctors who ordered more routine tests (perhaps some inappropriate or unnecessary) on behalf of their patients would also order more disease‐specific tests (or cancer‐specific tests) as screening tests. This is a reasonable assumption that cannot be proven as the data linking family doctors to breast, cervix and colon screening testing is incomplete. We assumed the rates of UPC tests from 2008 to 2012 would reflect practice for the few years before 2008.

The complete linked dataset for a very large study population and their doctors is the strength of this study; however, there are potential limitations. First, we chose an informal test selection process instead of a more rigorous modified Delphi process. We felt this was appropriate for our question as were looking for common tests ordered by family physicians on a background of Choosing Wisely and common sense. It is unlikely that different tests would have been selected by a more time consuming and expensive process. Second, in the absence of any relevant literature on the comparative clinical impact of test overuse and underuse, the authors assumed that the cutpoints of 25%, 50% or 100% more tests had clinical relevance. We did post hoc explore other statistical options such as standard deviations and there was no difference in the overall results (data not included). Third, we could not analyze cancer rates by Stage or extent of disease as "stage data" was not completely or reliability available for the 11 sites during the study time. A future study with "stage data" might compare the overuse of tests and early stage disease. Fourth, we could not assess the indications for the tests including patient wishes. Fifth, there were missing patients including 263 478 who could not be assigned to a UPC and women who gave birth during the study period (7773) as they would have had more routine tests. Patients who became ineligible for health care coverage after 2008 (109 271) were included until ineligibility. We excluded over 12,000 family physicians including those without information in the ICES dataset, UPCs with small practices and UPCs who were not involved in full‐time primary care noting that there is no reason to suspect that similar doctors with similar patients would not have similar testing behavior within our health care system. Sixth, our results are specific to the 23 tests, the 11 common cancers and the universal health care system in Ontario and may not be generalizable to other tests, other cancers and other health care funding systems. Finally, in Ontario, routine laboratory tests done on outpatients at hospitals are not billed to OHIP and therefore do not appear in our datasets. We therefore may have underestimated the rates of routine laboratory tests but this represents only 5% of tests[35](#cam41925-bib-0035){ref-type="ref"} and is unlikely to influence our results.

5. CONCLUSION {#cam41925-sec-0026}
=============

Due to the wide variation in the ordering of common and routine laboratory and imaging tests, family doctors in Ontario Canada could be classified into Typical, Higher and Lower testers. As predicted by the literature on OverDiagnosis, the patients of physicians who were Higher testers were diagnosed more often with thyroid and prostate cancers. The overuse of medical tests in a health care system leads to the OverDiagnosis with downstream implications of overtreatment and increased costs. Mechanisms to address and correct overuse of tests through education would result in reductions in morbidity and cost.
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